Archives
Cediranib (AZD2171): Potent ATP-Competitive VEGFR Tyrosin...
Cediranib (AZD2171): Potent ATP-Competitive VEGFR Tyrosine Kinase Inhibitor for Cancer Research
Executive Summary: Cediranib (AZD2171) is a selective, orally bioavailable VEGFR tyrosine kinase inhibitor with sub-nanomolar potency against VEGFR-2, making it a leading reagent for angiogenesis inhibition in cancer research (APExBIO, product page). Its mechanism involves competitive inhibition at the ATP-binding site of VEGFRs, suppressing VEGF-induced phosphorylation, and modulating the PI3K/Akt/mTOR pathway (Schwartz 2022). Cediranib also displays activity against PDGFR family kinases, including c-Kit and Flt-3, with IC50 values in the low micromolar range. Quantitative in vitro benchmarks confirm robust inhibition of proliferation and angiogenic signaling in cancer cells. The agent’s solubility and storage profile require careful workflow integration to maximize experimental stability and reproducibility.
Biological Rationale
Angiogenesis, the formation of new blood vessels, is a hallmark of tumor progression. Vascular endothelial growth factor receptors (VEGFRs) are key mediators of angiogenic signaling. Overexpression or hyperactivation of VEGFRs contributes to tumor growth, metastasis, and poor patient prognosis (Schwartz 2022). Targeting VEGFR signaling can disrupt nutrient supply to tumors and inhibit downstream pathways such as PI3K/Akt/mTOR, essential for cell survival and proliferation. Cediranib (AZD2171) was developed as a highly potent, selective inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, providing a tool to dissect and block angiogenic processes in cancer models (APExBIO).
Mechanism of Action of Cediranib (AZD2171)
Cediranib acts as a competitive inhibitor at the ATP-binding site of VEGFR tyrosine kinases. It displays an IC50 of <1 nM for VEGFR-2 (KDR), and sub-nanomolar activity for VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4) (APExBIO). The compound blocks VEGF-induced receptor phosphorylation, thereby halting downstream activation of the PI3K/Akt/mTOR pathway and other angiogenic signals (Schwartz 2022). In addition to VEGFRs, Cediranib inhibits kinases such as PDGFR-α, PDGFR-β, c-Kit, CSF-1R, and Flt-3 with IC50 values ranging from 0.002 to >1 μM. This extended profile is due to structural homology within the kinase family. By suppressing Akt phosphorylation at Ser473, Cediranib reduces cell survival signaling and proliferation, effectively blocking tumor angiogenesis and growth.
Evidence & Benchmarks
- Cediranib inhibits VEGFR-2 kinase activity with an IC50 of <1 nM in purified enzyme assays, outperforming many legacy inhibitors (APExBIO).
- In vitro, Cediranib blocks VEGF-induced phosphorylation of Akt (Ser473) in endothelial cells, with measurable reduction at nanomolar concentrations (Schwartz 2022).
- Fractional cell viability and proliferation studies demonstrate dose-dependent inhibition of tumor cell growth when Cediranib is added at 1–100 nM in serum-supplemented media (37°C, 5% CO2, 48–72 hr) (Schwartz 2022).
- Benchmarks in multi-kinase profiling show Cediranib’s selectivity for VEGFRs over off-target kinases in a panel of 50+ tyrosine kinases (supplemental tables, Schwartz 2022).
This article extends the mechanistic clarity provided by 'Cediranib (AZD2171): Optimizing VEGFR Tyrosine Kinase Inh...' by providing quantitative, peer-reviewed benchmarks and stability guidance not previously detailed. For lab-specific protocols and troubleshooting, see 'Cediranib (AZD2171) in Cancer Research: Real-World Lab Sc...', which this article complements by adding molecular selectivity data. For strategic translational insights, 'Cediranib (AZD2171): Redefining VEGFR Tyrosine Kinase Inh...' covers clinical workflow aspects beyond the scope of this in vitro-focused dossier.
Applications, Limits & Misconceptions
Cediranib (AZD2171) is used in:
- Investigating VEGFR-mediated angiogenesis and tumor progression in vitro.
- Dissecting PI3K/Akt/mTOR pathway dynamics in cancer cell lines.
- Comparative kinase inhibitor profiling against multi-kinase panels.
- Developing preclinical models of anti-angiogenic therapy resistance.
However, several boundaries and misconceptions must be addressed.
Common Pitfalls or Misconceptions
- Off-target effects at high concentrations: Cediranib can inhibit kinases outside the VEGFR family when used at micromolar concentrations, potentially confounding results.
- Limited efficacy in water or ethanol: The compound is insoluble in water and ethanol, requiring DMSO for preparation (≥22.52 mg/mL at room temperature).
- Stability constraints: Cediranib solutions are not stable for long-term storage and should be freshly prepared before use.
- Not a pan-angiogenesis inhibitor: Cediranib’s efficacy is restricted to VEGFR- and certain PDGFR-mediated pathways; it does not block all forms of angiogenesis.
- In vitro to in vivo translation: Cellular potency may not directly predict in vivo anti-tumor efficacy due to pharmacokinetics and microenvironment differences (Schwartz 2022).
Workflow Integration & Parameters
For optimal results, Cediranib (AZD2171) should be dissolved in DMSO (≥22.52 mg/mL) and stored at -20°C as a solid. Working solutions should be prepared fresh, with minimal freeze-thaw cycles to preserve potency. Recommended in vitro dosing ranges from 1–100 nM for VEGFR pathway inhibition in cell-based assays (37°C, 5% CO2). Control for DMSO concentration, as excessive levels may affect cell viability independently. The compound is best suited for studies focusing on VEGF-induced signaling, angiogenesis, and PI3K/Akt/mTOR pathway modulation. APExBIO supplies Cediranib (AZD2171) under SKU A1882, with detailed handling protocols on the product page.
Conclusion & Outlook
Cediranib (AZD2171) remains a gold standard for selective inhibition of VEGFR tyrosine kinases in cancer research. Its nanomolar potency, broad kinase profiling, and reliable inhibition of angiogenesis have made it essential for dissecting tumor growth pathways. Despite its strengths, users must heed solubility and stability constraints for reproducible results. Future research may leverage Cediranib’s mechanistic precision in next-generation in vitro models and combinatorial drug screens (Schwartz 2022). For product details and ordering, consult APExBIO’s Cediranib (AZD2171) A1882 kit page.